A Phase II Trial of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin) in Patients With Metastatic Melanoma.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2014
At a glance
- Drugs Pelareorep (Primary)
- Indications Malignant melanoma
- Focus Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.